EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The highs and lows of serous ovarian cancer

Rachel N Grisham iD, Beryl L Manning-Geist, M Herman Chui

Cancer · 2023

DOI: 10.1002/cncr.34903 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, 2023. Verfasst von Rachel N Grisham und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low‐grade serous ovarian cancer was initially described as a distinct type of rare epithelial ovarian cancer 20 years ago; however, only recently have physicians begun to leverage the understanding of the clinical behavior and molecular profile of this disease for treatment. The use of routine next‐generation sequencing has allowed a deeper understanding of the molecular drivers of this disease and shown how molecular alterations in mitogen‐activated protein kinase pathway genes such as KRAS and BRAF can affect overall prognosis and disease behavior. The use of targeted therapies, including MEK inhibitors, BRAF kinase inhibitors, and other investigational targeted therapies are changing the way this disease is viewed and treated. In addition, endocrine therapy can provide prolonged disease stability with generally mild toxicity, as well as promising response rates in recent studies examining combination therapy with CDK 4/6 inhibitors in the upfront and recurrent setting. Once seen merely as a chemo‐resistant form of ovarian cancer, recent studies have worked to harness the unique features of low‐grade serous ovarian cancer to provide individualized treatment options for patients with this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousHumansFemaleCarcinoma, Ovarian EpithelialNeoplasm GradingPrognosisProto-Oncogene Proteins B-rafMutation

Stichwörter der Autor:innen

Low-grade serousMAPKMEKovarian cancerrare tumors

Substanzen

Proto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Rachel N Grisham

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Grisham, R. N., Manning-Geist, B. L., & Chui, M. H. (2023). The highs and lows of serous ovarian cancer. Cancer. https://doi.org/10.1002/cncr.34903

Vancouver

Grisham RN, Manning-Geist BL, Chui MH. The highs and lows of serous ovarian cancer. Cancer. 2023. doi:10.1002/cncr.34903

BibTeX
@article{Grisham2023,
  author = {Grisham, Rachel N and Manning-Geist, Beryl L and Chui, M Herman},
  title = {The highs and lows of serous ovarian cancer},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34903}
}
Kostenlos starten →